This educational program is intended for hematologists, medical oncologists, nurses, pharmacists, and other healthcare professionals who treat patients with R/R MM
Upon completion of this activity, participants should be able to:
Disclosure and Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Clinical Care Options, LLC (CCO). Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Paul G. Richardson, MD
Associate Professor of Medicine
Harvard Medical School
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Paul G. Richardson, MD: consultant/advisor/speaker: AstraZeneca, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Karyopharm, Novartis, Oncopeptides, Sanofi, Secura Bio, Takeda; researcher: Celgene/Bristol Myers Squibb, Karyopharm, Oncopeptides, Takeda.
Natalie S. Callander, MD
Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Natalie S. Callander, MD, has no relevant financial relationships to disclose.
Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Noopur Raje, MD: consultant/advisor/speaker: AbbVie, Amgen, Bluebird Bio, Bristol-Myers Squibb, Caribou Biosciences & Immuneel, Janssen, Pfizer, Sanofi, Takeda; researcher: Bluebird Bio.
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose.
Associate Scientific Director
Terrence Fagan has no relevant financial relationships to disclose.
Associate Managing Editor
Krista Marcello has no relevant financial relationships to disclose.
Ramya Moorthy, has no relevant financial relationships to disclose.
Kevin Obholz, PhD
Editorial Director, Hematology/Oncology
Kevin Obholz, PhD, has no relevant financial relationships to disclose.
Shara Pantry, PhD
Associate Scientific Director
Shara Pantry, PhD, has no relevant financial relationships to disclose.
Brian Purves, PharmD, MBA
Brian Purves, PharmD: The following relationships have ended within the last 24 months: Employee of AstraZeneca with focus in Medical Information for Respiratory Inhaled-Symbicort.
Timothy A. Quill, PhD
Senior Managing Editor
Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Kristen Rosenthal, PhD
Kristen M. Rosenthal, PhD, has no relevant financial relationships to disclose.
Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN
Department of Urology
University of Virginia
Terran Sims, MSN, ACNP-C, CNN, COCN-C: consultant/advisor/speaker: Coloplast Corp.
Justine Stanley, MSc
Justine Stanley, MSc, has no relevant financial relationships to disclose.
Saranya Vijayakumar, PhD
Saranya Vijayakumar, PhD, has no relevant financial relationships to disclose.
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 12, 2022, through October 11, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
This program has been made available online.
The goal of this activity is to improve the knowledge and competence of learners in selecting individualized treatments for patients with R/R MM.